Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc., a pioneering biotechnology firm based in the United States, focuses on the development of innovative immunotherapies for cancer and autoimmune diseases. Founded in 2018, the company has rapidly advanced its proprietary Neoleukin platform, which leverages computational design to create novel protein therapeutics. Headquartered in Seattle, Washington, Neoleukin operates primarily within the biopharmaceutical industry, aiming to revolutionise treatment options through its unique approach to protein engineering. The company’s lead product candidates, designed to mimic the activity of naturally occurring cytokines, stand out for their potential to enhance immune responses while minimising side effects. With a commitment to scientific excellence, Neoleukin Therapeutics has positioned itself as a notable player in the immunotherapy landscape, attracting significant attention for its innovative solutions and promising clinical developments.
DitchCarbon Score
How does Neoleukin Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Neoleukin Therapeutics, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Neoleukin Therapeutics, Inc.'s reported carbon emissions
Neoleukin Therapeutics, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures. The company has not established any documented reduction targets or climate pledges, which suggests a lack of formal commitments to reducing greenhouse gas emissions at this time. It is important to note that Neoleukin Therapeutics, Inc. is a merged entity, and any potential emissions data or climate initiatives may be inherited from its corporate family. However, no specific emissions data or climate commitments have been cascaded from parent or related organisations. As the company continues to develop its sustainability strategy, stakeholders may look for future announcements regarding emissions tracking and reduction initiatives.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Neoleukin Therapeutics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
